BUSINESS SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Business Segment Information [Text Block]

BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting future periods.

Product revenues were as follows:

	Three Months Ended March 31,
Dollars in Millions	2016		2015
Oncology
Empliciti (elotuzumab)	$	28	$	—
Erbitux* (cetuximab)	—		165
Opdivo (nivolumab)	704		40
Sprycel (dasatinib)	407		375
Yervoy (ipilimumab)	263		325
Cardiovascular
Eliquis (apixaban)	734		355
Immunoscience
Orencia (abatacept)	475		400
Virology
Baraclude (entecavir)	291		340
Hepatitis C Franchise (a)	427		264
Reyataz (atazanavir sulfate) Franchise	221		294
Sustiva (efavirenz) Franchise(b)	273		290
Neuroscience
Abilify* (aripiprazole)(c)	33		554
Mature Products and All Other	535		639
Total Revenues	$	4,391	$	4,041

*	Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information is included at the end of this quarterly report on Form 10-Q.
(a)	Includes Daklinza (daclatasvir) revenues of $420 million and $180 million for the three months ended March 31, 2016 and 2015, respectively, and Sunvepra (asunaprevir) revenues of $7 million and $84 million for the three months ended March 31, 2016 and 2015, respectively.
(b)	Includes alliance revenue of $241 million and $251 million for the three months ended March 31, 2016 and 2015, respectively.
(c)	Includes alliance revenue of $508 million for the three months ended March 31, 2015. BMS's U.S. commercialization rights to Abilify* expired in April 2015.

The composition of total revenues was as follows:

	Three Months Ended March 31,
Dollars in Millions	2016		2015
Net product sales	$	3,964	$	3,059
Alliance revenues	409		955
Other revenues	18		27
Total Revenues	$	4,391	$	4,041